Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC)

项目总结/摘要 新出现的和重新出现的传染病（EID）暴发在以下国家发生的频率越来越高： 南美洲/中美洲、西非/中非和东南亚的高风险地区对美国构成威胁 States.记录在案的研究基础设施方面的差距限制了迅速应对这些疫情的能力。 为了应对这一挑战，国家过敏和传染病研究所（NIAID）正在建立 新兴传染病研究中心网络（EIDRC-Net），以提高对EID的认识; 充分利用现有的NIAID国际努力;发展有效、灵活和快速地 爆发研究反应。RTI国际和杜克大学提议建立EIDRC 协调中心（EIDRC CC）。RTI-Duke CC将支持EIDRC网络，该网络将包括 通过实现以下目标，加强EIDRC、研究中心、CC和NIAID的协调： 通过提供行政、通信、后勤和业务支持进行合作;（2） 通过协调和支持可持续的、可扩展的和适应性强的 研究基础设施，以优化疫情间隔期间的资源和知识共享， 在疾病爆发期间迅速有效地作出反应;（3）通过使用 严格的数据和样本管理系统，内置数据质量保证;（4）确保 通过统一标准操作规程， EIDRC-Net网站和跨网络程序的持续审计;以及（5）开发下一代 调查人员和国内科学家通过建立一个试点研究计划，确定，资金， 指导高质量的EIDRC申请人。通过成功地实现我们的五个具体目标，RTI杜克大学 该团队将通过建立可扩展的系统、流程和 资源，不仅提供必要的基础设施，以促进EIDRC-Net的性能和携带 在疫情间隔期间，CC的核心功能，但也可以增强和扩展，以支持CC 研究疫情爆发期间的快速反应活动。EIDRC CC团队将由多个负责人共同领导 研究者Donald Brambilla博士（RTI）是一名生物统计学家，接受过生物学高级培训， 经验丰富的CC领导人，和迈克尔安东尼（托尼）穆迪，医学博士（杜克），儿科传染病 他是杜克人类疫苗研究所的专家和首席医疗官。他们一起带来了广泛的 科学知识，领导能力，行政经验和国际研究专长，包括在 与EID研究最相关的地理位置。这种伙伴关系还利用了 RTI是一家大型非营利研究机构，在75个国家设有地区和项目办事处。 杜克大学是一所以尖端医学而闻名的一流大学， 研究和国家的最先进的，NIAID资助的区域生物遏制实验室的家。

PROJECT SUMMARY/ABSTRACT Emerging and re-emerging infectious disease (EID) outbreaks that are occurring with increasing frequency in high-risk areas in South/Central America, West/Central Africa, and Southeast Asia are a threat to the United States. Documented gaps in research infrastructure limit the capacity to rapidly respond to these outbreaks. To address this challenge, the National Institute of Allergy and Infectious Diseases (NIAID) is establishing the Emerging Infectious Disease Research Centers Network (EIDRC-Net) to improve knowledge of EIDs; leverage existing NIAID international efforts; and develop the capacity to mount effective, flexible, and rapid outbreak research responses. RTI International and Duke University propose to establish the EIDRC Coordination Center (EIDRC CC). The RTI-Duke CC will support the EIDRC-Net, which will comprise the EIDRCs, research sites, the CC, and NIAID by realizing the following aims: (1) enhance EIDRC coordination and collaboration by providing administrative, communications, logistical, and operational support; (2) amplify NIAID's capabilities and reach by coordinating and supporting a sustainable, scalable, and adaptable research infrastructure to optimize resources and knowledge sharing during inter-outbreak periods and to respond rapidly and effectively during outbreaks; (3) ensure quality and consistency of study data by using rigorous data and specimen management systems with built-in data quality assurance; (4) ensure quality of biospecimens, assays, and reagents through harmonization of standard operating procedures across EIDRC-Net sites and ongoing audit of cross-network procedures; and (5) develop the next generation of investigators and in-country scientists by establishing a pilot research program that identifies, funds, and mentors high-quality EIDRC applicants. By successfully accomplishing our five specific aims, the RTI-Duke team will shift the outbreak research response paradigm by establishing scalable systems, processes, and resources that not only provide the necessary infrastructure to facilitate EIDRC-Net performance and carry out CC core functions during inter-outbreak periods, but also can be enhanced and expanded to bolster CC research surge response activities during outbreaks. The EIDRC CC team will be co-led by multiple Principal Investigators Donald Brambilla, PhD (RTI), a biostatistician with advanced training in biology and an experienced CC leader, and Michael Anthony (Tony) Moody, MD (Duke), a pediatric infectious disease specialist and Chief Medical Officer of the Duke Human Vaccine Institute. Together they bring extensive scientific expertise, leadership, administrative experience, and international research expertise, including in geographic locations most relevant to the study of EIDs. This partnership also leverages the operational efficiency of RTI, a large nonprofit research organization with regional and project offices in over 75 countries, with the scientific rigor of Duke University, a premier university known for its cutting-edge medical research and home to a state-of-the-art, NIAID-funded Regional Biocontainment Laboratory.